Also trades as: 0RC7.L (LSE) · $vol 0M
HNSA.ST STO
Hansa Biopharma AB (publ)
1W: +2.5%
1M: -25.4%
3M: -4.0%
YTD: -10.3%
1Y: +5.9%
3Y: -26.6%
5Y: -73.0%
kr 33.18 ($3.30)
-0.94 (-2.75%)
Weekly Expected Move ±6.2%
kr 29
kr 31
kr 33
kr 35
kr 37
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$1.2B
+45.7% ▲
5Y CAGR: -4.0%
Total Liabilities
$1.3B
-10.0% ▼
5Y CAGR: +45.4%
Shareholders Equity
-$84M
+85.7% ▲
Cash & Investments
$701M
+73.0% ▲
5Y CAGR: -12.6%
Total Debt
$934M
-13.5% ▼
5Y CAGR: +184.1%
Net Debt
$233M
-65.5% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $651M | $1.5B | $732M | $405M | $701M |
| Short-Term Investments | $238M | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $889M | $1.5B | $732M | $405M | $701M |
| Net Receivables | $11M | $65M | $78M | $146M | $89M |
| Inventory | $242K | $973K | $2M | $3M | $6M |
| Other Current Assets | $40M | $61M | $40M | $14M | $0 |
| Total Current Assets | $942M | $1.6B | $855M | $585M | $797M |
| Property, Plant & Equip. | $46M | $36M | $27M | $18M | $13M |
| Goodwill & Intangibles | $29M | $47M | $136M | $197M | $231M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $126M |
| Other Non-Current Assets | -$4M | $0 | $0 | $0 | $0 |
| Total Non-Current Assets | $70M | $83M | $163M | $215M | $370M |
| Total Assets | $1.0B | $1.7B | $1.0B | $801M | $1.2B |
| — Liabilities — | |||||
| Accounts Payable | $53M | $62M | $87M | $38M | $66M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $137M |
| Deferred Revenue | $25M | $40M | $0 | $0 | $0 |
| Other Current Liabilities | $8M | $54M | $180M | $208M | $197M |
| Total Current Liabilities | $171M | $265M | $321M | $256M | $411M |
| Long-Term Debt | $0 | $763M | $845M | $1.1B | $786M |
| Other Non-Current Liab. | $8M | $6M | $5M | $63M | $50M |
| Total Non-Current Liabilities | $84M | $820M | $865M | $1.1B | $840M |
| Total Liabilities | $255M | $1.1B | $1.2B | $1.4B | $1.3B |
| — Equity — | |||||
| Common Stock | $46M | $55M | $55M | $68M | $0 |
| Retained Earnings | -$1.9B | -$2.5B | -$3.3B | -$4.1B | $0 |
| Accumulated OCI | $127K | $13K | -$408K | $942K | $0 |
| Total Stockholders Equity | $758M | $603M | -$168M | -$590M | -$84M |
| Total Liabilities & Equity | $1.0B | $1.7B | $1.0B | $801M | $1.2B |
| — Key Metrics — | |||||
| Total Debt | $35M | $791M | $867M | $1.1B | $934M |
| Net Debt | -$616M | -$705M | $135M | $674M | $233M |
| Total Investments | $238M | $0 | $0 | $0 | $126M |